Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID Vaccine Distribution Plan From National Academies Leaves Room For Adjustments Based On Trial Results

Executive Summary

Draft allocation framework expects health care workers would take up much of the initial vaccine supply and suggests the elderly and people with two comorbid conditions receive vaccination next. NAM suggests states get a population-based allotment, leaving local officials to make many of the tough decisions under the framework, which could be adjusted based on clinical trial data. 

You may also be interested in...



After First COVID-19 Vaccine Approval, How Will Other Trials Maintain Placebo Control?

US FDA officials fear comparator arms would be unwieldy for ongoing trials as they consider alternative methods to measure efficacy if placebo controls can't be maintained for the studies of other candidate vaccines once a product is on the market.

Gottlieb: Staged Access To Coronavirus Vaccine Possible Through EUA

Former FDA Commissioner says agency could grant an EUA for a vaccine, but require it meet the standard for full approval, and then roll it out gradually with postmarket data collection.

Initial COVID-19 Vaccine Rollout Seems Bound To Disappoint

National Academy of Medicines draft on equitable COVID-19 vaccine allocation needs more overt strategies to address equity, commenters say. Meanwhile, competing national and state efforts to address COVID-19 vaccination allocation could lead to confusion as the country struggles to fairly divide limited resources among many high-risk populations.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel